Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Short-term Investments (2017 - 2025)

Dianthus Therapeutics has reported Short-term Investments over the past 8 years, most recently at $346.6 million for Q3 2025.

  • Quarterly results put Short-term Investments at $346.6 million for Q3 2025, up 40.08% from a year ago — trailing twelve months through Sep 2025 was $346.6 million (up 40.08% YoY), and the annual figure for FY2024 was $252.4 million, up 509.88%.
  • Short-term Investments for Q3 2025 was $346.6 million at Dianthus Therapeutics, up from $244.2 million in the prior quarter.
  • Over the last five years, Short-term Investments for DNTH hit a ceiling of $346.6 million in Q3 2025 and a floor of $15.0 million in Q2 2023.
  • Median Short-term Investments over the past 4 years was $64.7 million (2022), compared with a mean of $126.4 million.
  • Biggest five-year swings in Short-term Investments: plummeted 82.32% in 2023 and later surged 659.33% in 2024.
  • Dianthus Therapeutics' Short-term Investments stood at $60.1 million in 2022, then tumbled by 31.16% to $41.4 million in 2023, then surged by 509.88% to $252.4 million in 2024, then surged by 37.31% to $346.6 million in 2025.
  • The last three reported values for Short-term Investments were $346.6 million (Q3 2025), $244.2 million (Q2 2025), and $253.1 million (Q1 2025) per Business Quant data.